HIV infection and the liver: The importance of HCV-HIV coinfection and drug-induced liver injury

Shehzad Nawaz Merwat, John M. Vierling

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Hepatitis C virus-Human immunodeficiency virus (HCV-HIV) coinfections are identified in up to 30% of patients infected with HIV and in 8% of patients infected with HCV. Now that progression of HIV and deaths due to AIDS can be prevented by highly active antiretroviral therapy (HAART), it is clear that HCV coinfection is associated with accelerated progression to cirrhosis and increased liver-related morbidity and mortality. Antiviral therapy with pegylated interferon and ribavirin for HCV in HCV-HIV coinfected patients is less successful than in patients with HCV monoinfection, and HAART can cause drug-induced liver injury. Multiple barriers limit the number of HCV-HIV coinfected patients who receive antiviral therapy for HCV, and the role of orthotopic liver transplantation (OLT) in HIV monoinfected and HCV-HIV coinfected patients remains controversial. Clinical trials of HCV-specific protease or polymerase inhibitors combined with pegylated interferon and ribavirin are needed urgently in coinfected patients, both before and after OLT.

Original languageEnglish (US)
Pages (from-to)131-152
Number of pages22
JournalClinics in Liver Disease
Volume15
Issue number1
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Chemical and Drug Induced Liver Injury
Coinfection
Hepacivirus
HIV Infections
HIV
Liver
Ribavirin
Highly Active Antiretroviral Therapy
Liver Transplantation
Interferons
Antiviral Agents
Liver Cirrhosis
Acquired Immunodeficiency Syndrome
Peptide Hydrolases
Clinical Trials
Morbidity
Mortality
Therapeutics

Keywords

  • HAART
  • HCV-HIV coinfection
  • Hepatitis C virus
  • Hepatotoxicity
  • Human immunodeficiency virus
  • Pegylated interferon
  • Ribavirin

ASJC Scopus subject areas

  • Hepatology

Cite this

HIV infection and the liver : The importance of HCV-HIV coinfection and drug-induced liver injury. / Merwat, Shehzad Nawaz; Vierling, John M.

In: Clinics in Liver Disease, Vol. 15, No. 1, 02.2011, p. 131-152.

Research output: Contribution to journalArticle

@article{ac947d558a754ec686ae195915aadd53,
title = "HIV infection and the liver: The importance of HCV-HIV coinfection and drug-induced liver injury",
abstract = "Hepatitis C virus-Human immunodeficiency virus (HCV-HIV) coinfections are identified in up to 30{\%} of patients infected with HIV and in 8{\%} of patients infected with HCV. Now that progression of HIV and deaths due to AIDS can be prevented by highly active antiretroviral therapy (HAART), it is clear that HCV coinfection is associated with accelerated progression to cirrhosis and increased liver-related morbidity and mortality. Antiviral therapy with pegylated interferon and ribavirin for HCV in HCV-HIV coinfected patients is less successful than in patients with HCV monoinfection, and HAART can cause drug-induced liver injury. Multiple barriers limit the number of HCV-HIV coinfected patients who receive antiviral therapy for HCV, and the role of orthotopic liver transplantation (OLT) in HIV monoinfected and HCV-HIV coinfected patients remains controversial. Clinical trials of HCV-specific protease or polymerase inhibitors combined with pegylated interferon and ribavirin are needed urgently in coinfected patients, both before and after OLT.",
keywords = "HAART, HCV-HIV coinfection, Hepatitis C virus, Hepatotoxicity, Human immunodeficiency virus, Pegylated interferon, Ribavirin",
author = "Merwat, {Shehzad Nawaz} and Vierling, {John M.}",
year = "2011",
month = "2",
doi = "10.1016/j.cld.2010.09.012",
language = "English (US)",
volume = "15",
pages = "131--152",
journal = "Clinics in Liver Disease",
issn = "1089-3261",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - HIV infection and the liver

T2 - The importance of HCV-HIV coinfection and drug-induced liver injury

AU - Merwat, Shehzad Nawaz

AU - Vierling, John M.

PY - 2011/2

Y1 - 2011/2

N2 - Hepatitis C virus-Human immunodeficiency virus (HCV-HIV) coinfections are identified in up to 30% of patients infected with HIV and in 8% of patients infected with HCV. Now that progression of HIV and deaths due to AIDS can be prevented by highly active antiretroviral therapy (HAART), it is clear that HCV coinfection is associated with accelerated progression to cirrhosis and increased liver-related morbidity and mortality. Antiviral therapy with pegylated interferon and ribavirin for HCV in HCV-HIV coinfected patients is less successful than in patients with HCV monoinfection, and HAART can cause drug-induced liver injury. Multiple barriers limit the number of HCV-HIV coinfected patients who receive antiviral therapy for HCV, and the role of orthotopic liver transplantation (OLT) in HIV monoinfected and HCV-HIV coinfected patients remains controversial. Clinical trials of HCV-specific protease or polymerase inhibitors combined with pegylated interferon and ribavirin are needed urgently in coinfected patients, both before and after OLT.

AB - Hepatitis C virus-Human immunodeficiency virus (HCV-HIV) coinfections are identified in up to 30% of patients infected with HIV and in 8% of patients infected with HCV. Now that progression of HIV and deaths due to AIDS can be prevented by highly active antiretroviral therapy (HAART), it is clear that HCV coinfection is associated with accelerated progression to cirrhosis and increased liver-related morbidity and mortality. Antiviral therapy with pegylated interferon and ribavirin for HCV in HCV-HIV coinfected patients is less successful than in patients with HCV monoinfection, and HAART can cause drug-induced liver injury. Multiple barriers limit the number of HCV-HIV coinfected patients who receive antiviral therapy for HCV, and the role of orthotopic liver transplantation (OLT) in HIV monoinfected and HCV-HIV coinfected patients remains controversial. Clinical trials of HCV-specific protease or polymerase inhibitors combined with pegylated interferon and ribavirin are needed urgently in coinfected patients, both before and after OLT.

KW - HAART

KW - HCV-HIV coinfection

KW - Hepatitis C virus

KW - Hepatotoxicity

KW - Human immunodeficiency virus

KW - Pegylated interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=78649507293&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649507293&partnerID=8YFLogxK

U2 - 10.1016/j.cld.2010.09.012

DO - 10.1016/j.cld.2010.09.012

M3 - Article

C2 - 21111997

AN - SCOPUS:78649507293

VL - 15

SP - 131

EP - 152

JO - Clinics in Liver Disease

JF - Clinics in Liver Disease

SN - 1089-3261

IS - 1

ER -